Natural, efective and safe

SURFACEN® is a pig lung surfactant for the Respiratory Distress Syndrome
Pharmaceutical Form: Freeze-dried for endotracheal instillation

Registro sanitario en Cuba 0800

Each bulb contains:

Phospholipids ……………. 50,0 mg

Proteins  ………………… 0,3 a 0,7 mg

Other lipids ……………  2,3 a 3,3 mg

Sodium Chloride ……… 18,0mg

Its protein content consists of two hydrophobic proteins (SP-B and SP-C) of low molecular weight associated with the surfactant. It does not contain other hydrophilic proteins associated with the surfactant such as SP-A and SP-D.
Presentation: Box containing four bulbs | Stability: 24 months.
This drug is produced under the international guidelines of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP). The manufacture of the Active Pharmaceutical Ingredient (API), the evaluation of the final product, the batch release, storage and distribution are carried out at the National Center for Animal and Plant Health (CENSA); and the aseptic process: formulation, filling, freeze-drying, visual inspection, packaging and sampling at the National Center of Biological Products (BioCen), both institutions located in Mayabeque province, Cuba.

[censa_toggles accordion=”true”][censa_toggle title=”Therapeutic Indication”]

SURFACEN® is indicated for the treatment of the Newborn Respiratory Distress Syndrome (Hyaline Membrane Disease, HMD), and in adults, for the Acute Respiratory Distress Syndrome (ARDS).

SURFACEN® has contributed to the reduction of infant mortality (0.2 per thousand born alive) by the Hyaline Membrane disease of since it was registered in Cuba in 1995 to the present.

[/censa_toggle][censa_toggle title=”Publications”]

For further information

Lic. Odalys Uffo Reinosa, Dr.C.

Tel.: (5347) 863897 – 849166

Fax: (5347) 863206

SURFACEN®